The latest innovation in blood thinners could make investors heart-stopping profits.
Despite competition from Johnson & Johnson's Xarelto, Bristol-Myers Squibb and Pfizer's Eliquis is dominating the market for factor Xa inhibitors.
Our Foolish contributors are keeping a close eye on Bristol-Myers Squibb, Gilead Sciences, and Lexicon Pharmaceuticals in the first quarter of 2017.
Is small Exelixis a better stock pick for investors than big Bristol-Myers Squibb?
All finger-pointing begins and ends with cancer immunotherapy Opdivo.
A major patent settlement between Merck & Co. and Bristol-Myers Squibb was one of last week's biggest healthcare stories.
Our team of Foolish contributors thinks these seven stocks are all strong buys right now.
From a big-time patent settlement between Merck & Co. and Bristol-Myers Squibb, to Johnson & Johnson's earnings, to Aetna and Humana's $37 billion merger bust, we dive into the details behind last week's biggest healthcare stories.
These cheap stocks could be money in your pocket over the long term.
Bristol-Myers Squibb's executives acknowledge stiff competition from Merck, Roche, and Gilead Sciences.